Benita Tamrazi

Prof. Benita Tamrazi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Cancer Cell
Verified
Journal Article
Closed access
CCChan Chung
Chan Chung
SSStefan R. Sweha
Stefan R. Sweha
DPDrew Pratt
Drew Pratt
BTBenita Tamrazi
Benita Tamrazi
PPPooja Panwalkar
Pooja Panwalkar
SVSriram Venneti
Sriram Venneti

6 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PPPooja Panwalkar
Pooja Panwalkar
BTBenita Tamrazi
Benita Tamrazi
DDDerek Dang
Derek Dang
CCChan Chung
Chan Chung
SSStefan Sweha
Stefan Sweha
SVSriram Venneti
Sriram Venneti
Childhood posterior fossa group A ependymomas demonstrate integrated metabolic and epigenetic pathways that can be disrupted by metformin.

1 February 2017 in Neuroimaging Clinics Of North America
Verified
Journal Article
Closed access
BTBenita Tamrazi
Benita Tamrazi
MNMarvin Nelson
Marvin Nelson
SBStefan Bluml
Stefan Bluml

1 June 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
TWTai-Wei Wu
Tai-Wei Wu
BTBenita Tamrazi
Benita Tamrazi
SSSadaf Soleymani
Sadaf Soleymani
ISIstvan Seri
Istvan Seri
SNShahab Noori
Shahab Noori

1 May 2018 in Radiology
Verified
Journal Article
Closed access
BTBenita Tamrazi
Benita Tamrazi
BNBinh Nguyen
Binh Nguyen
CLChia-Shang J. Liu
Chia-Shang J. Liu
CAColleen G. Azen
Colleen G. Azen
MNMary B. Nelson
Mary B. Nelson
MNMarvin D. Nelson
Marvin D. Nelson
Brain irradiation and primary brain tumors affect signal intensity within the dentate nucleus and globus pallidus independent of gadolinium administration in pediatric patients. PurposeTo determine whether whole-brain irradiation, chemotherapy, and primary brain pathologic conditions affect magnetic resonance (MR) imaging signal changes in pediatric patients independent of...

6 November 2019 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MAMariam S. Aboian
Mariam S. Aboian
ETE. Tong
E. Tong
DSD.A. Solomon
D.A. Solomon
CKCassie Kline
Cassie Kline
AGA. Gautam
A. Gautam
SCS. Cha
S. Cha
BACKGROUND AND PURPOSE: Diffuse midline gliomas with histone H3 K27M mutation are biologically aggressive tumors with poor prognosis defined as a new diagnostic entity in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. There are no qualitative imaging differences (enhancement, border, or central necrosis) between histone H3 wildtype and H3 K27M-mutant diffuse midline gliomas. Herein, we evaluated the utility of diffusion-weighted imaging to distinguish H3 K27M-mutant from histone H3 wildtype diffuse midline gliomas. MATERIALS AND METHODS: We identified 31 pediatric patients (younger than 21 years of age) with diffuse gliomas centered in midline structures that had undergone assessment for histone H3 K27M mutation. We measured ADC within these tumors using a voxel-based 3D whole-tumor measurement method. RESULTS: Our cohort included 18 infratentorial and 13 supratentorial diffuse gliomas centered in midline structures. Twenty-three (74%) tumors carried H3-K27M mutations. There was no difference in ADC histogram parameters (mean, median, minimum, maximum, percentiles) between mutant and wild-type tumors. Subgroup analysis based on tumor location also did not identify a difference in histogram descriptive statistics. Patients who survived 1 year (1.46 × 10−3mm2/s; 95% CI, 1.19–1.67; P < .06). Average ADC values for diffuse midline gliomas were 1.28 × 10−3mm2/s (95% CI, 1.21–1.34) and 0.86 × 10−3mm2/s (95% CI, 0.69–1.01) for hemispheric glioblastomas with P < .05. CONCLUSIONS: Although no statistically significant difference in diffusion characteristics was found between H3-K27M mutant and H3 wildtype diffuse midline gliomas, lower diffusivity corresponds to a lower survival rate at 1 year after diagnosis. These findings can have an impact on the anticipated clinical course for this patient population and offer providers and families guidance on clinical outcomes.